Suppr超能文献

Concentration-effect relationships and individual responses to doxazosin in essential hypertension.

作者信息

Donnelly R, Elliott H L, Meredith P A, Reid J L

机构信息

University Department of Materia Medica, Stobhill General Hospital, Glasgow.

出版信息

Br J Clin Pharmacol. 1989 Nov;28(5):517-26. doi: 10.1111/j.1365-2125.1989.tb03537.x.

Abstract
  1. This study investigates aspects of the pharmacokinetics, pharmacodynamics and concentration-effect relationships in 10 patients with essential hypertension during acute and chronic treatment with doxazosin, an alpha 1-adrenoceptor antagonist. 2. Following the first dose of doxazosin (2 mg) there were significant reductions in blood pressure, increases in heart rate and in plasma noradrenaline, and parallel rightward shifts of the phenylephrine pressor response curves, consistent with alpha-adrenoceptor antagonism. There was no significant change in the pressor response to angiotensin II. 3. Using an integrated kinetic-dynamic model, individual blood pressure responsiveness was characterised as the fall in blood pressure (mm Hg) per unit drug concentration. Responsiveness to the first dose of doxazosin was directly correlated with the responsiveness after 1 and 6 weeks treatment although there was a systemic reduction (of approximately 30%) which occurred during the first week of treatment. 4. Neither the acute nor long-term responsiveness to doxazosin was related to age, plasma renin activity, plasma noradrenaline or the pretreatment sensitivity to phenylephrine. There was a significant relationship between responsiveness and the height of the initial (pretreatment) blood pressure. 5. Integration of pharmacokinetic and pharmacodynamic data provides a reproducible index of responsiveness which can be used to investigate the consistency of the long-term anti-hypertensive response, to identify factors which influence the magnitude of the response, and to optimise the choice of dose and dose interval.
摘要

相似文献

1
Concentration-effect relationships and individual responses to doxazosin in essential hypertension.
Br J Clin Pharmacol. 1989 Nov;28(5):517-26. doi: 10.1111/j.1365-2125.1989.tb03537.x.
2
Vascular pressor responses in treated and untreated essential hypertension.
J Cardiovasc Pharmacol. 1990 Aug;16(2):191-6. doi: 10.1097/00005344-199008000-00003.
3
Combination of nifedipine and doxazosin in essential hypertension.
J Cardiovasc Pharmacol. 1992 Apr;19(4):479-86. doi: 10.1097/00005344-199204000-00002.
4
Doxazosin, an alpha 1-adrenoceptor antagonist: pharmacokinetics and concentration-effect relationships in man.
Br J Clin Pharmacol. 1983 Jun;15(6):719-25. doi: 10.1111/j.1365-2125.1983.tb01556.x.
7
Doxazosin in patients with hypertension.
Eur J Clin Pharmacol. 1988;35(1):21-4. doi: 10.1007/BF00555502.
10
The antihypertensive effects of doxazosin: a clinical overview.
Br J Clin Pharmacol. 1986;21 Suppl 1(Suppl 1):83S-90S. doi: 10.1111/j.1365-2125.1986.tb02858.x.

引用本文的文献

3
Clinical pharmacokinetics of vasodilators. Part II.
Clin Pharmacokinet. 1998 Jul;35(1):9-36. doi: 10.2165/00003088-199835010-00002.
4
The implications of noncompliance with antihypertensive medication.
Drugs. 1996 Aug;52(2):186-95. doi: 10.2165/00003495-199652020-00003.
5
Concentration-effect analysis of antihypertensive drug response. Focus on calcium antagonists.
Clin Pharmacokinet. 1994 Jun;26(6):472-85. doi: 10.2165/00003088-199426060-00005.
7
Pharmacokinetic-pharmacodynamic relationships of alpha-adrenoceptor antagonists.
Clin Pharmacokinet. 1989 Oct;17(4):264-74. doi: 10.2165/00003088-198917040-00004.
8
The description and prediction of antihypertensive drug response: an individualised approach.
Br J Clin Pharmacol. 1991 Jun;31(6):627-34. doi: 10.1111/j.1365-2125.1991.tb05584.x.

本文引用的文献

2
Responsiveness of hypertensive subjects to prazosin.
Clin Exp Pharmacol Physiol. 1980 Mar-Apr;7(2):215-7. doi: 10.1111/j.1440-1681.1980.tb00064.x.
3
Prazosin disposition in young and elderly subjects.
Br J Clin Pharmacol. 1981 Sep;12(3):401-4. doi: 10.1111/j.1365-2125.1981.tb01234.x.
4
Prazosin dynamics in hypertension: relationship to plasma concentration.
Clin Pharmacol Ther. 1981 Oct;30(4):447-54. doi: 10.1038/clpt.1981.187.
5
Prazosin kinetics in hypertension.
Clin Pharmacol Ther. 1981 Oct;30(4):439-46. doi: 10.1038/clpt.1981.186.
6
Prazosin plasma concentration and blood pressure reduction.
Hypertension. 1982 Jan-Feb;4(1):93-101. doi: 10.1161/01.hyp.4.1.93.
7
Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.
Clin Pharmacokinet. 1981 Nov-Dec;6(6):429-53. doi: 10.2165/00003088-198106060-00002.
8
Role of plasma kallikrein in the proteolytic activation of the renin-angiotensin system.
Clin Exp Hypertens (1978). 1980;2(3-4):575-92. doi: 10.3109/10641968009037131.
9
Determination of the vasodilator UK33274 by high-performance liquid chromatography using fluorescence detection.
J Chromatogr. 1980 Nov 14;221(1):193-5. doi: 10.1016/s0378-4347(00)81025-7.
10
Analysis of the pressor dose response.
Clin Pharmacol Ther. 1982 Oct;32(4):450-8. doi: 10.1038/clpt.1982.188.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验